Goldman Sachs Group Inc. Cuts Position in MediWound Ltd. $MDWD

Goldman Sachs Group Inc. reduced its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 39.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,610 shares of the biopharmaceutical company’s stock after selling 7,673 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.11% of MediWound worth $180,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Bank of America Corp DE lifted its position in MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 2,178 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in MediWound by 17.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 3,343 shares during the period. Silverberg Bernstein Capital Management LLC lifted its holdings in MediWound by 13.1% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company’s stock valued at $1,613,000 after acquiring an additional 12,060 shares during the last quarter. GAMMA Investing LLC lifted its stake in MediWound by 1,507.1% during the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,703 shares in the last quarter. Finally, Corebridge Financial Inc. lifted its position in shares of MediWound by 17.1% in the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 665 shares in the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on MDWD. Zacks Research lowered shares of MediWound from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Oppenheimer began coverage on MediWound in a report on Monday, June 2nd. They set an “outperform” rating and a $34.00 price objective for the company. Finally, Wall Street Zen lowered MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.25.

MediWound Price Performance

MDWD stock opened at $17.97 on Tuesday. The stock has a market capitalization of $194.22 million, a price-to-earnings ratio of -6.81 and a beta of 0.25. MediWound Ltd. has a fifty-two week low of $14.14 and a fifty-two week high of $22.50. The business’s fifty day moving average price is $18.00 and its two-hundred day moving average price is $18.48.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.68). MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. The business had revenue of $5.71 million during the quarter, compared to analyst estimates of $5.68 million. Research analysts expect that MediWound Ltd. will post -2.66 EPS for the current year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.